Extended Data Fig. 4: Characterization of the plasma cells (PCs) in the bone marrow of OPBG patients, as assessed by multiparametric flow-cytometry.
From: Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases
Percentage of bone marrow PCs expressing CD19+38high138−, 19+38high138+ and CD19−38high138+ are depicted for each OPBG patient, according to different time points. Bone marrow aspirate was not performed before treatment in patient cSLE-OPBG001, and the sample was not available at month 12 for patient JDM-OPBG002.
